Cellectar Biosciences, Inc. to Post Q2 2024 Earnings of ($0.37) Per Share, Roth Capital Forecasts (NASDAQ:CLRB)

Cellectar Biosciences, Inc. (NASDAQ:CLRB - Free Report) - Roth Capital increased their Q2 2024 earnings per share (EPS) estimates for Cellectar Biosciences in a research note issued to investors on Tuesday, May 14th. Roth Capital analyst J. Aschoff now expects that the biopharmaceutical company will earn ($0.37) per share for the quarter, up from their prior estimate of ($0.40). The consensus estimate for Cellectar Biosciences' current full-year earnings is ($1.85) per share. Roth Capital also issued estimates for Cellectar Biosciences' Q3 2024 earnings at ($0.38) EPS, Q4 2024 earnings at ($0.42) EPS and FY2025 earnings at $0.52 EPS.

Other research analysts also recently issued research reports about the company. StockNews.com raised Cellectar Biosciences to a "sell" rating in a report on Thursday, March 28th. Oppenheimer restated an "outperform" rating and issued a $12.00 price target (up previously from $11.00) on shares of Cellectar Biosciences in a research report on Thursday, March 28th. Finally, Roth Mkm upped their price target on Cellectar Biosciences from $20.00 to $28.00 and gave the stock a "buy" rating in a research report on Thursday, March 28th.

Cellectar Biosciences Trading Down 0.9 %

CLRB stock traded down $0.03 during trading on Thursday, reaching $3.33. The stock had a trading volume of 472,266 shares, compared to its average volume of 1,499,232. Cellectar Biosciences has a 52 week low of $1.36 and a 52 week high of $4.45. The stock's 50 day moving average is $3.49 and its two-hundred day moving average is $3.16. The firm has a market cap of $119.38 million, a PE ratio of -1.09 and a beta of 0.99.

Cellectar Biosciences (NASDAQ:CLRB - Get Free Report) last posted its earnings results on Wednesday, March 27th. The biopharmaceutical company reported ($0.66) earnings per share for the quarter, missing analysts' consensus estimates of ($0.59) by ($0.07).

Institutional Trading of Cellectar Biosciences

Institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. grew its holdings in Cellectar Biosciences by 2.3% during the 3rd quarter. Vanguard Group Inc. now owns 175,884 shares of the biopharmaceutical company's stock valued at $464,000 after buying an additional 3,911 shares in the last quarter. Acuta Capital Partners LLC purchased a new position in Cellectar Biosciences in the 3rd quarter worth about $320,000. ADAR1 Capital Management LLC purchased a new position in Cellectar Biosciences during the 4th quarter worth $3,817,000. AIGH Capital Management LLC raised its holdings in shares of Cellectar Biosciences by 182.7% in the fourth quarter. AIGH Capital Management LLC now owns 1,915,220 shares of the biopharmaceutical company's stock valued at $5,305,000 after acquiring an additional 1,237,709 shares in the last quarter. Finally, Worth Venture Partners LLC boosted its stake in shares of Cellectar Biosciences by 148.6% during the fourth quarter. Worth Venture Partners LLC now owns 693,909 shares of the biopharmaceutical company's stock valued at $1,922,000 after purchasing an additional 414,786 shares in the last quarter. Hedge funds and other institutional investors own 16.41% of the company's stock.

Cellectar Biosciences Company Profile

Cellectar Biosciences, Inc, a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r pediatric patients with head and neck cancer.